ORIC Stock Forecast: Oric Pharmaceuticals, Inc. Price Predictions for 2026-2027
The 16 Wall Street analysts covering Oric Pharmaceuticals, Inc. hold a median 12-month price target of $22 — +192.1% from the last close. Ticker Nerd's systematic factor model, run across ~4,300 US stocks, ranks it 53 of 100 as at 21 Nov 2026 — in the upper half.
One number for the whole business
Consensus tells you what everyone already believes. The model scores Oric Pharmaceuticals, Inc. on its factor families — the same systematic rank behind the Ticker Nerd portfolio.
Percentile across ~4,300 US stocks on Ticker Nerd’s systematic factor model. Higher is better. How the model is built and tested
Value (76): The shares cost little relative to the profits and assets behind them — which can mean the market is too gloomy, or that the business really is in trouble.
Revisions (23): Analysts have, on balance, been cutting their forecasts.
Built and run by Aslam Ghouse, an ex-Goldman Sachs systematic trader with 15+ years in markets.
ORIC stock forecast 2026-2027: analyst price targets & predictions
The bullish and bearish analyst opinions on ORIC, reported as data — targets and ratings, the market's view beside the model's.
Price targets and ratings are third-party analyst estimates, reported here as data. They are not Ticker Nerd forecasts, and they are frequently wrong.
Data provided by Twelve Data
The green dot is the last close — the median target sits +192.1% from it.
Of the 20 most recent actions, 4 moved their price target up and 3 moved it down.
| Date | Firm | Action | Rating | Target |
|---|---|---|---|---|
| 19 Nov 2026 | HC Wainwright & Co. | Maintains | Buy | $27 → $20 |
| 18 Nov 2026 | Wells Fargo | Maintains | Overweight | $25 → $23 |
| 17 Nov 2026 | BTIG | Reiterates | Buy | $26 |
| 17 Nov 2026 | Citigroup | Maintains | Buy | $16 → $17 |
| 28 Oct 2026 | BTIG | Reiterates | Buy | $26 |
| 27 Oct 2026 | Wedbush | Maintains | Outperform | $17 → $14 |
| 26 Oct 2026 | Stifel | Maintains | Buy | $14 → $18 |
| 14 Oct 2026 | JP Morgan | Maintains | Overweight | $23 → $26 |
| 5 Oct 2026 | Leerink Partners | Initiates | Outperform | $26 |
| 23 Sept 2026 | BTIG | Initiates | Buy | $26 |
| 10 Aug 2026 | HC Wainwright & Co. | Maintains | Buy | $25 → $27 |
| 8 June 2026 | HC Wainwright & Co. | Reiterates | Buy | $25 |
| 15 May 2026 | Goldman Sachs | Upgrade | Buy | — |
| 5 May 2026 | Citigroup | Maintains | Buy | — |
| 2 Apr 2026 | HC Wainwright & Co. | Reiterates | Buy | — |
| 1 Apr 2026 | Wedbush | Maintains | Outperform | — |
| 13 Mar 2026 | HC Wainwright & Co. | Reiterates | Buy | — |
| 24 Feb 2026 | Citigroup | Maintains | Buy | — |
| 24 Feb 2026 | HC Wainwright & Co. | Maintains | Buy | — |
| 24 Feb 2026 | Wedbush | Reiterates | Outperform | — |
Price targets and ratings are third-party analyst estimates, reported here as data. They are not Ticker Nerd forecasts, and they are frequently wrong.
Wall Street targets run 12 to 18 months out. No analyst publishes a 2030 price target for ORIC.
This page is one stock. Monday covers all of them.
ORIC appears in the Radar on the weeks it earns a place.
- Market Radar, every Monday: the week's biggest rank moves across ~4,300 US stocks, and the reason for each.
- The AI build-out map, free: every AI company we track on one page, with the model's Top picks in all four parts.
AI cloud capacity
MSFTAMZNGOOGLORCL
AI chips
NVDAAVGOAMDMU
AI networking and servers
ANETDELLLITECRDO
Data centre power
VRTCEGGEVVST
ORIC vs the S&P 500
Both lines are total return — dividends reinvested — so the comparison is honest on both sides.
Over the twelve months to 20 Nov 2026, Oric Pharmaceuticals, Inc. returned −35.9% against +6.9% for the S&P 500, dividends included.
Download this chart as an image — free to reuse; link this page as the source.
Data provided by Twelve Data
ORIC analyst estimate revisions
Not the forecast itself — the direction analysts are revising it. Revision direction is one of the model's factor families.
Financials
A margin means little on its own. Each bar marks where the figure sits across the whole US universe we score.
- Trailing P/E
- —
- Price / sales
- —
- Price / book
- 2.4×
- EV / EBITDA
- —
Cheaper than 37% of US stocks
- Revenue growth (YoY)
- —
- Earnings growth (YoY)
- —
- Gross margin
- —
- Operating margin
- —
- Net margin
- —
- Return on equity
- −41.8%
- Return on assets
- −26.8%
- Dividend yield
- —
Higher than 24% of US stocks
Higher than 16% of US stocks
Bars mark the percentile across the ~4,300 US stocks Ticker Nerd covers, among those reporting the figure.
Key statistics
The headline figures, each with its date. Every row carries its own link — cite it straight from here.
Oric Pharmaceuticals, Inc. has a market value of $800.3M and an enterprise value of $544.9M.
Revenue in the twelve months to 30 June 2026: $0.0.
Net income over the same four quarters: −$140.4M.
Diluted earnings per share, trailing twelve months: −$1.35.
Free cash flow in the twelve months to 30 June 2026: −$112.3M.
Oric Pharmaceuticals, Inc. employs 119 people.
Data provided by Twelve Data
ORIC and its peers
The nearest names by industry and size, scored by the same model — like for like.
Take a look at ORIC’s peer groups, ranked by the model: healthcare stocks · biotech stocks.
Look up any of the roughly 4,300 stocks we score.
The rank is the raw material. Whether the rules would actually own Oric Pharmaceuticals, Inc. — and when they’d sell — is the membership. See the Ticker Nerd 20 →
Questions about ORIC
What is the ORIC stock price forecast for 2026-2027?
The 16 Wall Street analysts covering Oric Pharmaceuticals, Inc. have a median 12-month price target of $22, with estimates ranging from $14 to $26. These are third-party analyst estimates, not Ticker Nerd forecasts, and they are frequently wrong.
Is ORIC stock a buy right now?
Of the 16 analysts covering Oric Pharmaceuticals, Inc., 15 rate it a Buy, 1 a Hold and 0 a Sell. Ticker Nerd's systematic factor model ranks Oric Pharmaceuticals, Inc. 53 out of 100 across roughly 4,300 US stocks as at 21 Nov 2026. None of this is personal advice — it does not consider your circumstances.
How does Ticker Nerd's model rank ORIC?
As at 21 Nov 2026, Oric Pharmaceuticals, Inc. ranks 53 out of 100 on Ticker Nerd's systematic factor model — a percentile across roughly 4,300 US stocks, built from its factor families. Its strongest factor family is Value (76 of 100).
Will ORIC stock go up?
No one can know that. What the data says: the median 12-month target from 16 analysts implies +192.1% from the last close, and Ticker Nerd's factor model ranks Oric Pharmaceuticals, Inc. 53 out of 100 as at 21 Nov 2026. Analyst targets are third-party estimates and frequently wrong; none of this is personal advice.
What is the ORIC stock forecast for 2030?
No analyst covering Oric Pharmaceuticals, Inc. publishes a 2030 price target — Wall Street targets run 12 to 18 months out. Sites quoting a 2030 price for ORIC are extrapolating price history, which says nothing about the business. The furthest attributed numbers are the current analyst targets: $14 to $26 over the next 12 months.
How has ORIC stock performed over the past year?
Oric Pharmaceuticals, Inc. returned -35.9% over the 12 months to 20 Nov 2026, with dividends reinvested. Past performance does not indicate future returns.
What does Oric Pharmaceuticals, Inc. do?
Oric Pharmaceuticals, Inc. is a clinical-stage biopharmaceutical company focused on developing cancer therapies that address resistance to treatment. The company’s research pipeline centers on precision oncology, hormone-dependent cancers, and key tumor dependencies, with current programs designed to target mechanisms that limit the effectiveness of existing cancer medicines.
About Oric Pharmaceuticals, Inc.
Oric Pharmaceuticals, Inc. is a clinical-stage biopharmaceutical company focused on developing cancer therapies that address resistance to treatment. The company’s research pipeline centers on precision oncology, hormone-dependent cancers, and key tumor dependencies, with current programs designed to target mechanisms that limit the effectiveness of existing cancer medicines. Its product candidates include therapies in clinical development for genetically defined cancers and prostate cancer, along with additional discovery-stage oncology programs. Oric Pharmaceuticals operates as a single business segment and concentrates its efforts on advancing research, clinical development, and translational science for cancer treatment. The company is headquartered in South San Francisco, California, with additional operations supporting its development work in the United States. Its role in the market is to contribute experimental oncology candidates to the broader pipeline of targeted cancer therapeutics.
CEO Dr. Jacob M. Chacko M.B.A., M.D. · 119 employees · United States · https://www.oricpharma.com